Analysts at Jefferies see blockbuster potential in zorevunersen in Dravet syndrome, with sales potentially reaching $1 ...
Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the ...
Long-term Phase 1/2a and open label extension (OLE) data for zorevunersen on top of standard of care anti-seizure medicines (ASMs) demonstrate durable seizure reductions, including increases in ...
New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...
New analyses from the ongoing open label extension (OLE) studies and findings from electroencephalogram (EEG) assessments in ...
In late November and early December 2025, Biogen and its partners Eisai, Stoke Therapeutics and Dayra Therapeutics reported new clinical data and collaborations spanning Alzheimer’s disease, Dravet ...
Encoded Therapeutics has linked its Dravet syndrome gene therapy ETX101 to a 78% reduction in seizures, keeping the biotech ...
Discover Stoke Therapeutics' promising RNA therapies and market outlook. Learn the risks and commercial potential before investing in STOK shares.
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral ...
- Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback